Citations

Mayo Clinic

Showing 10 of 108523 citations.

Diagnosis of Obstructive Sleep Apnea in Adults
Morgenthaler, Timothy I.

Annals of Internal Medicine | March 16, 2015 | Volume: 162 | Issue: 6 | Pages: 455

10.7326/l15-5062 | PMID 25775321 Get It

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Forero‐Torres, Andres , Varley, Katherine E. , Abramson, Vandana G. , Liu, Minetta C. , Nanda, Rita , Storniolo, Anna Maria , Poznak, Catherine Van , Nangia, Julie R. , Irvin, William , Santos, Jennifer F. De Los , Haluska, Paul , Grizzle, William E. , Myers, R , Wolff, Antonio C. , Li, Yufeng , Vaklavas, Christos , Lin, Nancy U. , Rugo, Hope S. , Traina, Tiffany A , Patil, Sujata N , Krontiras, Helen , Wolff, Antonio C , Abramson, Vandana G

Clinical Cancer Research | March 16, 2015 | Volume: 21 | Issue: 12 | Pages: 2722-2729

10.1158/1078-0432.ccr-14-2780 | PMID 25779953 Get It

Abstract Purpose: Tigatuzumab (TIG), an agonistic anti-DR5 antibody, triggers apoptosis in DR5+ human tumor cells without crosslinking. TIG has strong in vitro/in vivo activity against basal-like breast cancer cells enhanced by chemotherapy agents. This study evaluates activity of TIG and chemotherapy in patients with metastatic triple-negative breast cancer (TNBC). Experimental Design: Randomized 2:1 phase II trial of albumin-bound paclitaxel (nab-PAC) ± TIG in patients with TNBC stratified by prior chemotherapy. Patients received nab-PAC weekly × 3 ± TIG every other week, every 28 days. Primary objective was within-arm objective response rate (ORR). Secondary objectives were safety, progression-free survival (PFS), clinical benefit, and TIG immunogenicity. Metastatic research biopsies were required. Results: Among 64 patients (60 treated; TIG/nab-PAC n = 39 and nab-PAC n = 21), there were 3 complete remissions (CR), 8 partial remissions (PR; 1 almost CR), 11 stable diseases (SD), and 17 progressive diseases (PD) in the TIG/nab-PAC arm (ORR, 28%), and no CRs, 8 PRs, 4 SDs, and 9 PDs in the nab-PAC arm (ORR, 38%). There was a numerical increase in CRs and several patients had prolonged PFS (1,025+, 781, 672, 460, 334) in the TIG/nab-PAC arm. Grade 3 toxicities were 28% and 29%, respectively, with no grade 4–5. Exploratory analysis suggests an association of ROCK1 gene pathway activation with efficacy in the TIG/nab-PAC arm. Conclusions: ORR and PFS were similar in both. Preclinical activity of TIG in basal-like breast cancer and prolonged PFS in few patients in the combination arm support further investigation of anti-DR5 agents. ROCK pathway activation merits further evaluation. Clin Cancer Res; 21(12); 2722–9. ©2015 AACR. See related article by Paoletti et al., p. 2771
What to do With Wake-Up Stroke
Rubin, Mark N. , Barrett, Kevin M.

The Neurohospitalist | March 16, 2015 | Volume: 5 | Issue: 3 | Pages: 161-172

10.1177/1941874415576204 | PMID 26288674 Get It

Wake-up stroke, defined as the situation where a patient awakens with stroke symptoms that were not present prior to falling asleep, represents roughly 1 in 5 acute ischemic strokes and remains a therapeutic dilemma. Patients with wake-up stroke were excluded from most ischemic stroke treatment trials and are often not eligible for acute reperfusion therapy in clinical practice, leading to poor outcomes. Studies of neuroimaging with standard noncontrast computed tomography (CT), magnetic resonance imaging (MRI), and multimodal perfusion-based CT and MRI suggest wake-up stroke may occur shortly before awakening and may assist in selecting patients for acute reperfusion therapies. Pilot studies of wake-up stroke treatment based on these neuroimaging features are promising but have limited generalizability. Ongoing randomized treatment trials using neuroimaging-based patient selection may identify a subset of patients with wake-up stroke that can safely benefit from acute reperfusion therapies.
How should children with West syndrome be efficiently and accurately investigated? Results from the National Infantile Spasms Consortium
Shellhaas, Renée A. , Joshi, Charuta , Keator, Cynthia, Kumar, Shilpi, Mitchell, Wendy G. , Nickels, Katherine , Berg, Anne T. , Gaillard, William D. , Wusthoff, Courtney J. , Yozawitz, Elissa , Goodkin, Howard P. , Wirrell, Elaine C., Wirrell, Elaine , Shellhaas, Renée A , Gaillard, William D , Yozawitz, Elissa G , Berg, Anne T , Nickels, Katherine C , Wusthoff, Courtney J

Epilepsia | March 16, 2015 | Volume: 56 | Issue: 4 | Pages: 617-625

10.1111/epi.12951 | PMID 25779538 Get It

Summary Objective To prospectively evaluate the etiology of new‐onset infantile spasms and evaluate the yield of genetic and metabolic investigations in those without obvious cause after initial clinical evaluation and magnetic resonance imaging ( MRI ). Methods Twenty‐one U.S. pediatric epilepsy centers prospectively enrolled infants with newly diagnosed West syndrome in a central database. Etiology and investigations performed within 3 months of diagnosis were documented. Results From June 2012 to June 2014, a total of 251 infants were enrolled (53% male). A cause was identified in 161 (64.4%) of 250 cases (genetic,14.4%; genetic‐structural, 10.0%; structural‐congenital, 10.8%; structural‐acquired, 22.4%; metabolic, 4.8%; and infectious, 2.0%). An obvious cause was found after initial clinical assessment (history and physical examination) and/or MRI in 138 of 161, whereas further genetic and metabolic studies were revealing in another 23 cases. Of 112 subjects without an obvious cause after initial evaluation and MRI , 81 (72.3%) had undergone genetic testing, which showed a causal abnormality in 23.5% and a variant of unknown significance in 14.8%. Although metabolic studies were done in the majority (serum, 79.5%; urine, 69.6%; and cerebrospinal fluid [ CSF ], 38.4%), these revealed an etiology in only five cases (4.5%). No correlation was found between type of health insurance (public vs. private) and either genetic or metabolic testing. Significance Clinical evaluation and MRI provide a specific diagnosis in 55% of children presenting with West syndrome. We propose that a cost‐effective workup for those without obvious cause after initial clinical evaluation and MRI includes an array comparative genomic hybridization ( aCGH ) followed by an epilepsy gene panel if the microarray is not definitive, serum lactate, serum amino acids, and urine organic acids.
Impact of Surgical Ventricular Reconstruction on Sphericity Index in Patients with Ischaemic Cardiomyopathy: Follow-Up from the STICH Trial
Choi, Jin‐Oh , Daly, Richard C. , Lin, Grace , Lahr, Brian D. , Wiste, Heather J. , Beaver, Thomas M. , Malinowski, Marcin , Friedrich, Ivar , Rouleau, Jean L. , Favaloro, Roberto , Lang, Iréne , Milano, Carmelo A. , Lee, Kerry L., Oh, Jae K. , Iacovoni, Attilio , Sopko, George S. , White, Harvey Douglas , Jones, Robert H. , Velazquez, Eric J.

European Journal of Heart Failure | March 16, 2015 | Volume: 17 | Issue: 4 | Pages: 453-463

10.1002/ejhf.256 | PMID 25779355 Get It

Abstract Aims We sought to evaluate associations between baseline sphericity index (SI) and clinical outcome, and changes in SI after coronary artery bypass graft (CABG) surgery with or without surgical ventricular reconstruction (SVR) in ischaemic cardiomyopathy patients enrolled in the SVR study (Hypothesis 2) of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. Methods and results Among 1000 patients in the STICH SVR study, we evaluated 546 patients (255 randomized to CABG alone and 291 to CABG + SVR) whose baseline SI values were available. SI was not significantly different between treatment groups at baseline. After 4 months, SI had increased in the CABG + SVR group, but was unchanged in the CABG alone group (0.69 ± 0.10 to 0.77 ± 0.12 vs. 0.67 ± 0.07 to 0.66 ± 0.09, respectively; P < 0.001). SI did not significantly change from 4 months to 2 years in either group. Although LV end-systolic volume and EF improved significantly more in the CABG + SVR group compared with CABG alone, the severity of mitral regurgitation significantly improved only in the CABG alone group, and the estimated LV filling pressure (E/A ratio) increased only in the CABG + SVR group. Higher baseline SI was associated with worse survival after surgery (hazard ratio 1.21, 95% confidence interval 1.02 − 1.43; P = 0.026). Survival was not significantly different by treatment strategy. Conclusion Although SVR was designed to improve LV geometry, SI worsened after SVR despite improved LVEF and smaller LV volume. Survival was significantly better in patients with lower SI regardless of treatment strategy.
Outcomes of Nonsevere Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated With Glucocorticoids
Miloslavsky, Eli M. , Seo, Philip , Langford, Carol A. , Hoffman, Gary S., Kallenberg, Cees G. M., Clair, E. W. St., Tchao, Nadia K., Ding, Linna , Iklé, David , Villareal, M., Lim, Noha , Brunetta, P., Stone, John H., Brunetta, Paul , Specks, Ulrich , Merkel, Peter A. , Spiera, Robert , Fervenza, Fernando C. , Monach, Paul A.

Arthritis & Rheumatology | March 16, 2015 | Volume: 67 | Issue: 6 | Pages: 1629-1636

10.1002/art.39104 | PMID 25776953 Get It

ObjectiveNonsevere relapses are more common than severe relapses in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV), but their clinical course and treatment outcomes remain largely unexamined. We undertook this study to analyze the outcomes of patients with nonsevere relapses in the Rituximab in ANCA‐Associated Vasculitis (RAVE) trial who were treated with prednisone according to a prespecified protocol.MethodsRAVE was a randomized, double‐blind, placebo‐controlled trial comparing rituximab (RTX) to cyclophosphamide (CYC) followed by azathioprine (AZA) for induction of remission. Patients who experienced nonsevere relapses between months 1 and 18 were treated with a prednisone increase without a concomitant change in their nonglucocorticoid immunosuppressants, followed by a taper.ResultsForty‐four patients with a first nonsevere relapse were analyzed. In comparison to the 71 patients who maintained relapse‐free remission over 18 months, these patients were more likely to have proteinase 3–ANCAs, diagnoses of granulomatosis with polyangiitis (Wegener's), and a history of relapsing disease at baseline. A prednisone increase led to remission in 35 patients (80%). However, only 13 patients (30%) were able to maintain second remissions through the followup period (mean 12.5 months); 31 patients (70%) had a second disease relapse, 14 of them with severe disease. The mean time to second relapse was 9.4 months (4.7 months in the group treated with RTX versus 13.7 months in the group treated with CYC/AZA; P < 0.01). Patients who experienced nonsevere relapses received more glucocorticoids than those who maintained remission (6.7 grams versus 3.8 grams; P < 0.01).ConclusionTreatment of nonsevere relapses in AAV with an increase in glucocorticoids is effective in restoring temporary remission in the majority of patients, but recurrent relapses within a relatively short interval remain common. Alternative treatment approaches are needed for this important subset of patients.
Dermatopathologists’ Opinions About the Quality of Clinical Information in the Skin Biopsy Requisition Form and the Skin Biopsy Care Process
Wong, Christina , Peters, Margot S. , Tilburt, Jon C. , Comfere, Nneka I.

American Journal of Clinical Pathology | March 16, 2015 | Volume: 143 | Issue: 4 | Pages: 593-597

10.1309/ajcphpg6dqfbkkur | PMID 25780013 Get It

Gastroenterology: Small bowel intussusception from metastatic melanoma with retained video capsule
Le, ST, Nguyen, Ba D.

Journal of Gastroenterology and Hepatology | March 16, 2015 | Volume: 30 | Issue: 4 | Pages: 650-650

10.1111/jgh.12858 | PMID 25776957 Get It

COMP-Ang1 Potentiates EPC Treatment of Ischemic Brain Injury by Enhancing Angiogenesis Through Activating AKT-mTOR Pathway and Promoting Vascular Migration Through Activating Tie2-FAK Pathway
Moon, Hyo Eun , Hur, Jin , Jun, Jong Kwan , Kim, Hyo‐Soo , Paek, Seung Leal, Kim, In Kyeong , Hwang, Jae Ha , Kim, Dong Gyu , Kim, Dong Gyu, Sung, Young Chul , Koh, Gou-Young, Song, Chang W, Lee, BongHee , Paek, Sun Ha , Byun, Kyunghee , Park, Hyung Woo , Kim, Jin Hyun , Park, Joong Shin

Experimental Neurobiology | March 16, 2015 | Volume: 24 | Issue: 1 | Pages: 55-70

10.5607/en.2015.24.1.55 | PMID 25792870 Get It